Last reviewed · How we verify
Beclomethasone Dipropionate/Formoterol Fumarate
Beclomethasone dipropionate reduces airway inflammation via glucocorticoid receptor activation, while formoterol fumarate bronchodilates by stimulating beta-2 adrenergic receptors.
Beclomethasone dipropionate reduces airway inflammation via glucocorticoid receptor activation, while formoterol fumarate bronchodilates by stimulating beta-2 adrenergic receptors. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Beclomethasone Dipropionate/Formoterol Fumarate |
|---|---|
| Also known as | Foster NEXThaler®, BDP/FF |
| Sponsor | Alfredo Antonio Chetta |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
This is a combination inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA). Beclomethasone dipropionate suppresses inflammatory cytokines and immune cell recruitment in the airways. Formoterol fumarate activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improved airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness/anxiety
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: